Clinical Trials Logo

Clinical Trial Summary

Smokers are highly reactive to smoking-related stimuli and report that this cue reactivity (CR) is a major obstacle to quitting. To date, no pharmacologic methods attenuate CR, and attempts to diminish it with traditional cue exposure treatment (CET) have not proven effective. The proposed study will test a highly novel cue-based smoking treatment adjunct combining an Approach/Avoidance Task (AAT) with brain stimulation via tDCS applied to the dorsolateral prefrontal cortex (dlPFC) during personalized multi-cue exposure; the goal of which is to discover an effective means of reducing cue reactivity and daily smoking, and increasing intent and confidence to quit, among high treatment-interest smokers.


Clinical Trial Description

Exposure to smoking-related cues robustly increases self-report craving and immediate subsequent smoking. This cue-reactivity (CR) is an often-reported obstacle to quitting among smokers. Unlike methods to diminish abstinence-induced craving, which have been highly successful with the advent of nicotine replacement therapies (NRTs), pharmacotherapies have not been shown to diminish smoking-related reactivity to cues. Past behavioral methods to reduce smokers' CR, most commonly extinction training through cue-exposure treatment (CET), have also consistently failed. Review of past CET studies reveals that this failure is largely due to several methodological shortcomings including: (1) presenting only proximal cues (e.g., cigarettes, ashtrays), (2) conducting passive unreinforced exposure to these limited cues, and (3) achieving only limited new learning. The researchers extensive past cue work makes them uniquely qualified to remedy these flaws by designing and testing novel CET methodology incorporating contemporary techniques and technology to reduce CR and relieve smokers of this ubiquitous source of relapse risk. The researchers propose three methods to improve CET. First, using well-tested methods for personalizing smoking cues and presenting numerous proximal, environment, and people cues in combination, the proposed cue exposure will better capture and target the cue-rich situations most likely to trigger smokers' strongest CR. Second, rather than repeated passive unreinforced exposure to cues, smokers will engage in active re-training of approach biases toward their personal smoking stimuli using an Approach/Avoidance Task (AAT), a method shown to activate the dorsolateral prefrontal cortex (dlPFC), a brain region associated with both cognitive control over craving and deactivation of drug reward systems. Third, to enhance new learning, smokers will undergo non-invasive transcranial direct current brain stimulation (i.e., tDCS) of the dlPFC. Although the researchers propose each method, AAT and tDCS, should independently reduce smokers' CR to their most salient cues, providing AAT with simultaneous tDCS (AAT+tDCS) should synergistically attenuate CR by better increasing cortical excitability in the dlPFC. To assess this, a 2 x 2 active and sham-controlled test of AAT and tDCS during personalized multi-cue exposures will be used to examine pre-post training changes across several measures of smoking-related cue reactivity (cue-induced craving, cue-provoked smoking topography, and attentional bias measures of Evoked Response Potentials (ERPs) and reaction time), as well as changes in daily smoking and confidence and intent to quit pre-post training and at 1 week and 1-month follow up. The goal of this work is to develop an efficacious treatment adjunct that better prepares smokers to confront cues when they try to remain quit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05426460
Study type Interventional
Source University of Pittsburgh
Contact Cynthia Conklin, PhD
Phone 412-586-9840
Email conklinca@upmc.edu
Status Recruiting
Phase N/A
Start date April 29, 2022
Completion date May 2024

See also
  Status Clinical Trial Phase
Completed NCT03397511 - Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City N/A
Terminated NCT03576768 - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt N/A
Recruiting NCT03802019 - Cigarette Packaging of Low Nicotine Cigarettes N/A
Completed NCT03194256 - Evaluating New Nicotine Standards for Cigarettes - Project 3 N/A
Completed NCT04808609 - Smoking Cessation Pilot for People Living With HIV (PLWH) N/A
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Recruiting NCT03721822 - Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation Phase 1
Completed NCT05162820 - Impact of Solarplast® on Immunity in Active Smokers and Non-smokers N/A
Recruiting NCT03630614 - Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. Phase 3
Completed NCT03502200 - Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures N/A
Completed NCT05473585 - Impact of New Standards for Tobacco Products Among Dual E-Cigarette/Combusted Cigarette Users - Project 2 N/A
Completed NCT04115176 - GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis
Completed NCT04161144 - Enhancing Self Regulation Among Smokers Phase 2
Completed NCT03364751 - Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome N/A
Recruiting NCT05973981 - The Impact of Standardized Tobacco Product Packaging on Young Adults in the Retail Environment N/A
Recruiting NCT06190860 - Platelet Rich Fibrin Treatment for the Alveolar Ridge Preservation in Smokers N/A
Recruiting NCT03814434 - Surgical Treatment of Periimplantitis in Patients With Risk Factors N/A
Completed NCT03569748 - Heated Tobacco Products vs Electronic Cigarettes N/A
Completed NCT03500965 - Pictorial Warning Labels and Memory for Relative and Absolute Cigarette Health-risk Information Over Time in Teens N/A
Completed NCT03642041 - Study of Smoking Trajectory in Newly Diagnosis Lung Cancer Patients